Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial

Overview of attention for article published in JNCI: Journal of the National Cancer Institute, September 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news: 1 news outlet
twitter: 7 X users

facebook: 1 Facebook page
guideline: 8 clinical guideline sources

Readers on

mendeley: 213 Mendeley

So far, Altmetric has seen 7 X posts from 7 X users, with an upper bound of 35,353 followers.

RT @DrewMoghanaki: NSABP R04 phase III published for #rectalcancer. Oxaliplatin only adds toxicity. Xel=5FU. #radonc https://t.co/oJqNGwfWLq

NSABP R04 phase III published for #rectalcancer. Oxaliplatin only adds toxicity. Xel=5FU. #radonc https://t.co/oJqNGwfWLq

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 3 additional X posts.